JPRN-jRCT2071260059 Investigational Regimen Post-essential thrombocythemia myelofibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines JPRN-jRCT2071260059—A Phase II Investigator-Initiated Clinical Trial Evaluating the Safety and Efficacy of Pitavastatin in Myelofibrosis Patients Treated with JAK Inhibitors—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2071260059 is a hot trial to watch
Post-essential thrombocythemia myelofibrosis is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. JPRN-jRCT2071260059 is notable because it tests Investigational Regimen in a Phase 2 design while 36 1 serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.
PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2071260059 |
| Official title | A Phase II Investigator-Initiated Clinical Trial Evaluating the Safety and Efficacy of Pitavastatin in Myelofibrosis Patients Treated with JAK Inhibitors |
| Phase / status | Phase 2 / Not yet recruiting |
| Intervention | Investigational Regimen |
| Sponsor | Not reported |
| Geography | Japan |
| Enrollment | 24 |
| Primary endpoint | Not reported in English |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | 2030-03-31 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. Allocation is Non-Randomized, masking is Open Label, and the intervention model is Single Group Assignment. Enrollment of 24 participants across Japan shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
- Primary:Not reported in English
- Primary: Proportion of participants who achieved a reduction of at least one grade in bone marrow fibrosis score at Week 36 compared with baseline.
- Secondary: Proportion of participants who achieved a reduction of at least one grade in bone marrow fibrosis score at Weeks 24 and 48 compared with baseline. Proportion of participants who achieved a reduction of at least one grade in bone marrow fibrosis score at any time point after treatment initiation compared with baseline. Proportion of participants with improvement in hemoglobin levels at Weeks 24, 36, and 48 after treatment initiation. Proportion of participants who met the Gale criteria for transfusion independence at Weeks 24, 36, and 48 after treatment initiation. Proportion of participants with a platelet count >= 100,000 /uL at Weeks 24, 36, and 48 after treatment initiation. Change in spleen volume from baseline at Weeks 24, 36, and 48 after treatment initiation. Change in total symptom score (MPN-SAF TSS) from baseline at Weeks 24, 36, and 48 after treatment initiation. Change in splenomegaly, as assessed by spleen length below the left costal margin, from baseline at Weeks 24, 36, and 48 after treatment initiation. Incidence of adverse events. Incidence of adverse events for which a causal relationship to the investigational product cannot be ruled out (adverse drug reactions). Incidence of serious adverse events for which a causal relationship to the investigational product cannot be ruled out (serious adverse drug reactions). Dose of JAK inhibitor. Comparison of efficacy-related endpoints, including bone marrow fibrosis score, with those of the registry cohort. Dose of pitavastatin.
- Secondary:24 48 1 1 24 36 48 24 36 48 Gale criteria 24 36 48 ≥10x10^4/μL 24 36 48 24 36 48 (MPN-SAF TSS) 24 36 48 ( ) ( ) JAK
Benchmark readouts in the surrounding field
- Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study (Phase 3): AE(led to discontinuation) = 5.0 % ; AE(led to discontinuation) = 13.0 %
- A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201) (Phase 2): Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) = 26.8 percentage of participants (95% Confidence Interval, 14.2 - 42.9)
- A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer (Phase 3): OS(Median) = 13.7 months (95% Confidence Interval, 11.2 - 16.2); OS(Median): Hazard Ratio (HR) = 0.661(95% CI, 0.553 - 0.790), P-Value = <0.0001
These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor:connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Investigational Regimen — structured asset context should be refreshed as the program evolves.
Company & Deal Intelligence context: Sponsor information not reported.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: comparative data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
JPRN-jRCT2071260059 is a focused lens on Post-essential thrombocythemia myelofibrosis development. Its value will be determined by whether Investigational Regimen can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.
Ready to reproduce this analysis?Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
